You are here

AbbVie

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

Fierce Pharma

Flag link:

Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

Motley Fool

Aimmune Therapeutics

Flag link:

AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial

AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial

Marketwatch

cilnical trials

Flag link:

AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

Fierce Pharma

small lymphocytic leukemia

Flag link:

AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.

AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.

Marketwatch

Boehringer Ingelheim

Flag link:

Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown

Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown

Fierce Biotech

Myovant Sciences

clinical trials

uterine fibroids

Flag link:

Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises

Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises

Endpoints

clinical trials

chronic lymphocytic leukemia

Flag link:

Why AbbVie Is in Better Shape Than You Might Think

Why AbbVie Is in Better Shape Than You Might Think

Motley Fool

Flag link:

Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline

Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline

Marketwatch

Flag link:

AbbVie wins hep C contract with Washington state in latest 'Netflix' deal

AbbVie wins hep C contract with Washington state in latest 'Netflix' deal

Biopharma Dive

Washington state

Flag link:

Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun

Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun

Fierce Pharma

Flag link:

What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

Motley Fool

Flag link:

AbbVie successor to Humira in psoriasis gains FDA approval

AbbVie successor to Humira in psoriasis gains FDA approval

BioCentury

Flag link:

Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay

Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay

Fierce Pharma

Vertex Pharmaceuticals

Flag link:

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Yahoo/Benzinga

Concert Pharmaceuticals

Edwards Lifesciences

Precision Biosciences

Boston Scientific

Bristol-Myers Squibb

Seattle Genetics

Flag link:

AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect

AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect

Motley Fool

Flag link:

3 Cancer Treatment Stocks on a Growth Trend

3 Cancer Treatment Stocks on a Growth Trend

Motley Fool

Flag link:

AbbVie (ABBV) Earnings Expected to Grow

AbbVie (ABBV) Earnings Expected to Grow

NASDAQ

Flag link:

Big spending from AbbVie, Pfizer pushes pharma's 2018 ad spend to $6.5B

Big spending from AbbVie, Pfizer pushes pharma's 2018 ad spend to $6.5B

Fierce Pharma

Flag link:

Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal

Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal

Fierce Pharma

Flag link:

Pages